The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Primary Hyperoxaluria Drug-Global Market Insights and Sales Trends 2025

Primary Hyperoxaluria Drug-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1813576

No of Pages : 91

Ask Your Query
Synopsis
The global Primary Hyperoxaluria Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Primary Hyperoxaluria Drug in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Primary Hyperoxaluria Drug market. ALLN-230, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the DCR-PHXC segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Primary Hyperoxaluria Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Primary Hyperoxaluria Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Primary Hyperoxaluria Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Primary Hyperoxaluria Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Primary Hyperoxaluria Drug covered in this report include Allena Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Intellia Therapeutics Inc and OxThera AB, etc.
The global Primary Hyperoxaluria Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Allena Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Intellia Therapeutics Inc
OxThera AB
Global Primary Hyperoxaluria Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Primary Hyperoxaluria Drug market, Segment by Type:
ALLN-230
DCR-PHXC
ALN-GO1
Others
Global Primary Hyperoxaluria Drug market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Primary Hyperoxaluria Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Primary Hyperoxaluria Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Primary Hyperoxaluria Drug Market Overview
1.1 Primary Hyperoxaluria Drug Product Overview
1.2 Primary Hyperoxaluria Drug Market Segment by Type
1.2.1 ALLN-230
1.2.2 DCR-PHXC
1.2.3 ALN-GO1
1.2.4 Others
1.3 Global Primary Hyperoxaluria Drug Market Size by Type
1.3.1 Global Primary Hyperoxaluria Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Primary Hyperoxaluria Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Primary Hyperoxaluria Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Primary Hyperoxaluria Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Primary Hyperoxaluria Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Primary Hyperoxaluria Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Primary Hyperoxaluria Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Primary Hyperoxaluria Drug Sales Breakdown by Type (2018-2023)
2 Global Primary Hyperoxaluria Drug Market Competition by Company
2.1 Global Top Players by Primary Hyperoxaluria Drug Sales (2018-2023)
2.2 Global Top Players by Primary Hyperoxaluria Drug Revenue (2018-2023)
2.3 Global Top Players by Primary Hyperoxaluria Drug Price (2018-2023)
2.4 Global Top Manufacturers Primary Hyperoxaluria Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Primary Hyperoxaluria Drug Market Competitive Situation and Trends
2.5.1 Primary Hyperoxaluria Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Primary Hyperoxaluria Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Hyperoxaluria Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Primary Hyperoxaluria Drug Market
2.8 Key Manufacturers Primary Hyperoxaluria Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Primary Hyperoxaluria Drug Status and Outlook by Region
3.1 Global Primary Hyperoxaluria Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Primary Hyperoxaluria Drug Historic Market Size by Region
3.2.1 Global Primary Hyperoxaluria Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Primary Hyperoxaluria Drug Sales in Value by Region (2018-2023)
3.2.3 Global Primary Hyperoxaluria Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Primary Hyperoxaluria Drug Forecasted Market Size by Region
3.3.1 Global Primary Hyperoxaluria Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Primary Hyperoxaluria Drug Sales in Value by Region (2024-2029)
3.3.3 Global Primary Hyperoxaluria Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Primary Hyperoxaluria Drug by Application
4.1 Primary Hyperoxaluria Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Primary Hyperoxaluria Drug Market Size by Application
4.2.1 Global Primary Hyperoxaluria Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Primary Hyperoxaluria Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Primary Hyperoxaluria Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Primary Hyperoxaluria Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Primary Hyperoxaluria Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Primary Hyperoxaluria Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Primary Hyperoxaluria Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Primary Hyperoxaluria Drug Sales Breakdown by Application (2018-2023)
5 North America Primary Hyperoxaluria Drug by Country
5.1 North America Primary Hyperoxaluria Drug Historic Market Size by Country
5.1.1 North America Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Primary Hyperoxaluria Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Primary Hyperoxaluria Drug Sales in Value by Country (2018-2023)
5.2 North America Primary Hyperoxaluria Drug Forecasted Market Size by Country
5.2.1 North America Primary Hyperoxaluria Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Primary Hyperoxaluria Drug Sales in Value by Country (2024-2029)
6 Europe Primary Hyperoxaluria Drug by Country
6.1 Europe Primary Hyperoxaluria Drug Historic Market Size by Country
6.1.1 Europe Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Primary Hyperoxaluria Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Primary Hyperoxaluria Drug Sales in Value by Country (2018-2023)
6.2 Europe Primary Hyperoxaluria Drug Forecasted Market Size by Country
6.2.1 Europe Primary Hyperoxaluria Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Primary Hyperoxaluria Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Primary Hyperoxaluria Drug by Region
7.1 Asia-Pacific Primary Hyperoxaluria Drug Historic Market Size by Region
7.1.1 Asia-Pacific Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Primary Hyperoxaluria Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Primary Hyperoxaluria Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Primary Hyperoxaluria Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Primary Hyperoxaluria Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Primary Hyperoxaluria Drug Sales in Value by Region (2024-2029)
8 Latin America Primary Hyperoxaluria Drug by Country
8.1 Latin America Primary Hyperoxaluria Drug Historic Market Size by Country
8.1.1 Latin America Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Primary Hyperoxaluria Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Primary Hyperoxaluria Drug Sales in Value by Country (2018-2023)
8.2 Latin America Primary Hyperoxaluria Drug Forecasted Market Size by Country
8.2.1 Latin America Primary Hyperoxaluria Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Primary Hyperoxaluria Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Primary Hyperoxaluria Drug by Country
9.1 Middle East and Africa Primary Hyperoxaluria Drug Historic Market Size by Country
9.1.1 Middle East and Africa Primary Hyperoxaluria Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Primary Hyperoxaluria Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Primary Hyperoxaluria Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Primary Hyperoxaluria Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Primary Hyperoxaluria Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Primary Hyperoxaluria Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Allena Pharmaceuticals Inc
10.1.1 Allena Pharmaceuticals Inc Company Information
10.1.2 Allena Pharmaceuticals Inc Introduction and Business Overview
10.1.3 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Allena Pharmaceuticals Inc Primary Hyperoxaluria Drug Products Offered
10.1.5 Allena Pharmaceuticals Inc Recent Development
10.2 Alnylam Pharmaceuticals Inc
10.2.1 Alnylam Pharmaceuticals Inc Company Information
10.2.2 Alnylam Pharmaceuticals Inc Introduction and Business Overview
10.2.3 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Alnylam Pharmaceuticals Inc Primary Hyperoxaluria Drug Products Offered
10.2.5 Alnylam Pharmaceuticals Inc Recent Development
10.3 Dicerna Pharmaceuticals Inc
10.3.1 Dicerna Pharmaceuticals Inc Company Information
10.3.2 Dicerna Pharmaceuticals Inc Introduction and Business Overview
10.3.3 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Dicerna Pharmaceuticals Inc Primary Hyperoxaluria Drug Products Offered
10.3.5 Dicerna Pharmaceuticals Inc Recent Development
10.4 Intellia Therapeutics Inc
10.4.1 Intellia Therapeutics Inc Company Information
10.4.2 Intellia Therapeutics Inc Introduction and Business Overview
10.4.3 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Intellia Therapeutics Inc Primary Hyperoxaluria Drug Products Offered
10.4.5 Intellia Therapeutics Inc Recent Development
10.5 OxThera AB
10.5.1 OxThera AB Company Information
10.5.2 OxThera AB Introduction and Business Overview
10.5.3 OxThera AB Primary Hyperoxaluria Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 OxThera AB Primary Hyperoxaluria Drug Products Offered
10.5.5 OxThera AB Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Primary Hyperoxaluria Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Primary Hyperoxaluria Drug Industrial Chain Analysis
11.4 Primary Hyperoxaluria Drug Market Dynamics
11.4.1 Primary Hyperoxaluria Drug Industry Trends
11.4.2 Primary Hyperoxaluria Drug Market Drivers
11.4.3 Primary Hyperoxaluria Drug Market Challenges
11.4.4 Primary Hyperoxaluria Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Primary Hyperoxaluria Drug Distributors
12.3 Primary Hyperoxaluria Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock